West Virginia Resident is First American to Receive Dicycloplatin Chemotherapy: A WVU Urologic Oncology Case Report

Author Info

Chad Morley Chad Crigger Jing Jie Yu Mohamad Salkini Shunchang Jiao

Corresponding Author

Jing Jie Yu
WVU Cancer Institute, School of Medicine, and School of Pharmacy, West Virginia University, Morgantown, WV, U.S.A

A B S T R A C T

A 65-year-old Caucasian male presented with increasing hematuria over four months in 2016. Work up and scans revealed a 1.5 cm bladder mass, with a subsequent pathologic diagnosis of non-invasive high-grade papillary urothelial carcinoma. The patient declined BCG Immunotherapy and traveled to China soon after diagnosis and transurethral resection for Dicycloplatin (DCP) chemotherapy. DCP is approved by the Chinese FDA but only available at present in military hospitals. It is similar in molecular structure to platinum-based chemotherapy drugs used in the West, its side effects reported to be more tolerable. The patient received 8 weeks of IV DCP chemotherapy – he only experienced mild nausea, myralgia, a relative leukopenia and thrombocytopenia (though within normal limits) and, importantly, no alopecia – then returned to WV for quarterly surveillance. No recurrence of tumor has been observed to date; the most recent cystoscopy was on April 24, 2018, 22 months after diagnosis and resection.

Article Info

Article Type

Case Report

Publication history

Received: Sun 24, Jun 2018
Accepted: Fri 06, Jul 2018
Published: Mon 16, Jul 2018

Copyright

© 2023 Jing Jie Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.COR.2018.02.005